Skip to content
Study details
Enrolling now

Bezafibrate Treatment for Bipolar Depression

Massachusetts General Hospital
NCT IDNCT02481245ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

30

Study length

about 8.1 years

Ages

18–65

Locations

1 site in MA

About this study

Researchers are testing whether bezafibrate, a medication, can help with bipolar depression. The trial will last 2970 days and involve monitoring changes in manic symptoms, suicidal thoughts, cognitive function, and adverse events. This proof-of-concept phase IIa trial aims to assess the safety and tolerability of bezafibrate added to anti-manic medication for bipolar depression.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Bezafibrate
PhasePhase 2
DrugBezafibrate
Routeoral
Primary goalChange from Baseline to Week 8 in Montgomery-Åsberg Depression Rating Scale (MADRS)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low11%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

bezafibrate

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Change from Baseline to Week 8 in Montgomery-Åsberg Depression Rating Scale (MADRS)

Secondary: Change from Baseline to Week 8 in Clinical Global Impressions Bipolar Scale (CGI-BP-S) score

Body systems

Psychiatry / Mental Health